Medtech Happy Hour: Demystifying Equity Compensation

We will review the basics of equity compensation (e.g., what are options? what is vesting? what is a preference?), the general levels of equity compensation by function and how the lifecycle of a Medtech company can impact the level of equity given.

Rick Geoffrion, President & Chief Executive Officer, Cyrano Therapeutics, Inc.  Rick currently serves as the Founder and Chief Executive Officer of Cyrano Therapeutics, a private company that has developed a treatment to restore the sense of smell and flavor in those who have lost it.  He is also a member of the Executive Committee and the Board of Directors for MDIC, the Medical Device Innovation Consortium, Chairman of Aventamed and Vice Chairman of The Mullings Group among other board positions.  Rick has more than 35 years of management experience in the medical device industry with more than 30 years in the cardiovascular device space. Rick has previously led the company foundation for four medical device companies: Mitralign (acquired by Edwards), CircuLite (acquired by HeartWare), FlowMedica (acquired by Angiodynamics) and X-Cell and guided the recapitalization and redirection of two other successful medical device companies: Impella (acquired by Abiomed) and Pathway (acquired by Bayer). Mr. Geoffrion has served as the Chairman of Impella CardioSystems AG, CircuLite and FlowMedica, Inc.  He has also held executive positions at Invatec (acquired by Medtronic), PercuSurge (acquired by Medtronic), Boston Scientific, SciMed Life Systems (acquired by BSX), Olympus and Baxter.  Rick received a BSME and an MBA from the University of Connecticut.